News

Cyntellect has entered into a research collaboration agreement with the Boston University School of Medicine. The agreement focuses on advancing research in the roles of mitochondrial oxidative damage

MicroPhage has obtained CE Mark to market in Europe the first of its instrument-free, rapid tests based on its patented Bacteriophage amplification technology. The company’s initial commercial product

Bayer Schering Pharma (Bayer Schering) has completed the decentralised part of drug approval procedure in Europe for a new treatment of endometriosis called Visanne. Visanne is a once-daily

NutraRx has entered into a distributor partnership with Emerson Ecologics. Emerson Ecologics will now be carrying the entire NutraRx line, enabling practitioners to save valuable time and money

Pediapharm has launched EpiCeram, a skin barrier emulsion indicated for atopic dermatitis and other dry skin conditions. Earlier this year, Pediapharm had announced an agreement with Ceragenix Pharmaceuticals

Keryx Biopharmaceuticals (Keryx) has provided updated efficacy and safety data as well as new survival data on the clinical activity of KRX-0401 (perifosine) in combination with Bortezomib (Velcade)

Johnson & Johnson Pharmaceutical Research and Development (Johnson & Johnson) has reported results from the Phase III Einstein-Extension (EXT) clinical trial of the oral anticoagulant Rivaroxaban, which showed

Pharmacyclics has reported interim results from a Phase I/II study showing safety and clinical activity in patients with relapsed / recurrent non-hodgkin’s lymphoma (NHL) treated with its HDAC

ImmunoGen has reported positive clinical data with IMGN901 candidate in the treatment of relapsed and relapsed/refractory multiple myeloma (MM), including prolonged benefit in patients whose disease had progressed